| Name | Title | Contact Details |
|---|---|---|
Michael Schroeder |
General Counsel and Chief Compliance Officer | Profile |
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.
United Pharma is a Fullerton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
fusionmed is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Fralex Therapeutics is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The Company is building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable diseases. The BioBlast platforms are based on deep understandings of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.